Contact
searchSearch
HMP Global
Login

Oncology

Featured

Conference Coverage
Abemaciclib Plus Endocrine Therapy for HR-Positive, HER2-Negative Advanced Breast Cancer
12/10/2025
Stephanie Holland
Results from the phase 3 AMBRE trial demonstrate that abemaciclib plus endocrine therapy significantly improves PFS compared with investigators choice chemotherapy in patients with HR-positive, HER2-negative advanced breast cancer and high...
Results from the phase 3 AMBRE trial demonstrate that abemaciclib plus endocrine therapy significantly improves PFS compared with investigators choice chemotherapy in patients with HR-positive, HER2-negative advanced breast cancer and high...
Results from the phase 3 AMBRE...
12/10/2025
Oncology
News
HER2 Alterations Signal Poorer Outcomes in Untreated RAS/BRAF Wild-Type Metastatic Colorectal Cancer
12/10/2025
Janelle Bradley
Among patients with RAS/BRAF wild-type metastatic colorectal cancer, those who harbor HER2 alterations experience significantly worse survival but show no differential benefit from first-line anti-EGFR or bevacizumab therapy, according to an...
Among patients with RAS/BRAF wild-type metastatic colorectal cancer, those who harbor HER2 alterations experience significantly worse survival but show no differential benefit from first-line anti-EGFR or bevacizumab therapy, according to an...
Among patients with RAS/BRAF...
12/10/2025
Oncology
Conference Coverage
Sacituzumab Govitecan Fails to Improve PFS in HR-Positive, HER2-Negative Metastatic Breast Cancer
12/10/2025
Stephanie Holland
According to results from the phase 3 ASCENT-07 trial, sacituzumab govitecan did not significantly improve progression-free survival compared to physician’s choice chemotherapy in previously treated HR-positive, HER2-negative locally advanced...
According to results from the phase 3 ASCENT-07 trial, sacituzumab govitecan did not significantly improve progression-free survival compared to physician’s choice chemotherapy in previously treated HR-positive, HER2-negative locally advanced...
According to results from the...
12/10/2025
Oncology
Johannes Holtschmidt, MD
Conference Coverage
Prognostic Value of Ki67 and Tumor-Infiltrating Lymphocytes in Residual Tumor Following Neoadjuvant Chemotherapy for TNBC
12/10/2025
Johannes Holtschmidt, MD, discusses results from a pooled analysis showing that Ki67 and tumor-infiltrating lymphocytes in residual tumor improve prognostic assessment for patients with triple-negative breast cancer who do not achieve...
Johannes Holtschmidt, MD, discusses results from a pooled analysis showing that Ki67 and tumor-infiltrating lymphocytes in residual tumor improve prognostic assessment for patients with triple-negative breast cancer who do not achieve...
Johannes Holtschmidt, MD,...
12/10/2025
Oncology
Quiz
FDA Approves Tarlatamab for Extensive-Stage Small Cell Lung Cancer
12/10/2025
Which of the following statements best reflects the efficacy outcomes that supported conversion of tarlatamab’s accelerated approval to traditional approval for previously treated ES-SCLC in the phase 3 DeLLphi-304 trial?
Which of the following statements best reflects the efficacy outcomes that supported conversion of tarlatamab’s accelerated approval to traditional approval for previously treated ES-SCLC in the phase 3 DeLLphi-304 trial?
Which of the following...
12/10/2025
Oncology
News
Consolidative Thoracic Radiotherapy Shows Limited Clinical Benefit in Extensive-Stage SCLC
12/10/2025
Stephanie Holland
According to results from the phase 2 SAKK 15-19 trial, consolidative thoracic radiotherapy after chemoimmunotherapy showed limited clinical benefit for patients with extensive-stage small cell lung cancer.
According to results from the phase 2 SAKK 15-19 trial, consolidative thoracic radiotherapy after chemoimmunotherapy showed limited clinical benefit for patients with extensive-stage small cell lung cancer.
According to results from the...
12/10/2025
Oncology
Conference Coverage
Niraparib Plus Dostarlimab Demonstrates Meaningful Neoadjuvant Activity in Germline BRCA1/2-Mutated TNBC
12/10/2025
Stephanie Holland
According to results from the phase 2 TBCRC 056 trial, neoadjuvant niraparib plus dostarlimab demonstrated clinically meaningful pathologic complete response activity among patients with germline BRCA1/2-mutated triple-negative breast cancer.
According to results from the phase 2 TBCRC 056 trial, neoadjuvant niraparib plus dostarlimab demonstrated clinically meaningful pathologic complete response activity among patients with germline BRCA1/2-mutated triple-negative breast cancer.
According to results from the...
12/10/2025
Oncology
Wolfgang Janni, MD, PhD
Conference Coverage
Ribociclib Improves Outcomes in HR-Positive, HER2-Positive Metastatic Breast Cancer
12/09/2025
Wolfgang Janni, MD, PhD, discusses final efficacy results from the phase 3 DETECT V trial, which assessed trastuzumab, pertuzumab, and ribociclib paired with either chemotherapy-free or chemotherapy-based treatment strategies in patients with...
Wolfgang Janni, MD, PhD, discusses final efficacy results from the phase 3 DETECT V trial, which assessed trastuzumab, pertuzumab, and ribociclib paired with either chemotherapy-free or chemotherapy-based treatment strategies in patients with...
Wolfgang Janni, MD, PhD,...
12/09/2025
Oncology
Bilal Abid MD, MS, FACP, MRCP, FRCP
Conference Coverage
Germinal Center B-Cell Subtype DLBCL Associated With Superior Outcomes After CAR T-Cell Therapy
12/09/2025
According to results presented by Bilal Abid, MD, at the 2025 ASH Annual Meeting, patients with GCB subtype R/R diffuse large B-cell lymphoma experienced significantly better survival after CAR T-cell therapy than those with non-GCB disease.
According to results presented by Bilal Abid, MD, at the 2025 ASH Annual Meeting, patients with GCB subtype R/R diffuse large B-cell lymphoma experienced significantly better survival after CAR T-cell therapy than those with non-GCB disease.
According to results presented...
12/09/2025
Oncology
Olalekan Oluwole, MD, MBBS
Conference Coverage
Healthcare Resource Utilization for Patients With DLBCL and MM Comparable Between New and Established CAR T-Cell Therapy Centers
12/09/2025
Newly authorized US CAR T-cell therapy centers deliver healthcare resources for DLBCL and MM comparable to established programs, according to a real-world analysis presented by Olalekan Oluwole, MD, MBBS, at the 2025 ASH Annual Meeting.
Newly authorized US CAR T-cell therapy centers deliver healthcare resources for DLBCL and MM comparable to established programs, according to a real-world analysis presented by Olalekan Oluwole, MD, MBBS, at the 2025 ASH Annual Meeting.
Newly authorized US CAR T-cell...
12/09/2025
Oncology
Veronika Bachanova, MD, PhD
Conference Coverage
Emergence of Novel Composite End Points Toxicity/PFS and Toxicity-Free CR to Benchmark Safety and Efficacy of CAR-T Cell Therapy for DLBCL
12/08/2025
At the ASH 2025 Annual Meeting, Veronika Bachanova, MD, PhD, explains data on the value of novel composite end-points toxicity/progression-free survival (tfPFS) and toxicity-free complete remission (tfCR100) for evaluating cell therapies for...
At the ASH 2025 Annual Meeting, Veronika Bachanova, MD, PhD, explains data on the value of novel composite end-points toxicity/progression-free survival (tfPFS) and toxicity-free complete remission (tfCR100) for evaluating cell therapies for...
At the ASH 2025 Annual Meeting,...
12/08/2025
Oncology

Videos

Johannes Holtschmidt, MD
Conference Coverage
Prognostic Value of Ki67 and Tumor-Infiltrating Lymphocytes in Residual Tumor Following Neoadjuvant Chemotherapy for TNBC
12/10/2025
Johannes Holtschmidt, MD, discusses results from a pooled analysis showing that Ki67 and tumor-infiltrating lymphocytes in residual tumor improve prognostic assessment for patients with triple-negative breast cancer who do not achieve...
Johannes Holtschmidt, MD, discusses results from a pooled analysis showing that Ki67 and tumor-infiltrating lymphocytes in residual tumor improve prognostic assessment for patients with triple-negative breast cancer who do not achieve...
Johannes Holtschmidt, MD,...
12/10/2025
Oncology
Wolfgang Janni, MD, PhD
Conference Coverage
Ribociclib Improves Outcomes in HR-Positive, HER2-Positive Metastatic Breast Cancer
12/09/2025
Wolfgang Janni, MD, PhD, discusses final efficacy results from the phase 3 DETECT V trial, which assessed trastuzumab, pertuzumab, and ribociclib paired with either chemotherapy-free or chemotherapy-based treatment strategies in patients with...
Wolfgang Janni, MD, PhD, discusses final efficacy results from the phase 3 DETECT V trial, which assessed trastuzumab, pertuzumab, and ribociclib paired with either chemotherapy-free or chemotherapy-based treatment strategies in patients with...
Wolfgang Janni, MD, PhD,...
12/09/2025
Oncology
Bilal Abid MD, MS, FACP, MRCP, FRCP
Conference Coverage
Germinal Center B-Cell Subtype DLBCL Associated With Superior Outcomes After CAR T-Cell Therapy
12/09/2025
According to results presented by Bilal Abid, MD, at the 2025 ASH Annual Meeting, patients with GCB subtype R/R diffuse large B-cell lymphoma experienced significantly better survival after CAR T-cell therapy than those with non-GCB disease.
According to results presented by Bilal Abid, MD, at the 2025 ASH Annual Meeting, patients with GCB subtype R/R diffuse large B-cell lymphoma experienced significantly better survival after CAR T-cell therapy than those with non-GCB disease.
According to results presented...
12/09/2025
Oncology
Olalekan Oluwole, MD, MBBS
Conference Coverage
Healthcare Resource Utilization for Patients With DLBCL and MM Comparable Between New and Established CAR T-Cell Therapy Centers
12/09/2025
Newly authorized US CAR T-cell therapy centers deliver healthcare resources for DLBCL and MM comparable to established programs, according to a real-world analysis presented by Olalekan Oluwole, MD, MBBS, at the 2025 ASH Annual Meeting.
Newly authorized US CAR T-cell therapy centers deliver healthcare resources for DLBCL and MM comparable to established programs, according to a real-world analysis presented by Olalekan Oluwole, MD, MBBS, at the 2025 ASH Annual Meeting.
Newly authorized US CAR T-cell...
12/09/2025
Oncology
Veronika Bachanova, MD, PhD
Conference Coverage
Emergence of Novel Composite End Points Toxicity/PFS and Toxicity-Free CR to Benchmark Safety and Efficacy of CAR-T Cell Therapy for DLBCL
12/08/2025
At the ASH 2025 Annual Meeting, Veronika Bachanova, MD, PhD, explains data on the value of novel composite end-points toxicity/progression-free survival (tfPFS) and toxicity-free complete remission (tfCR100) for evaluating cell therapies for...
At the ASH 2025 Annual Meeting, Veronika Bachanova, MD, PhD, explains data on the value of novel composite end-points toxicity/progression-free survival (tfPFS) and toxicity-free complete remission (tfCR100) for evaluating cell therapies for...
At the ASH 2025 Annual Meeting,...
12/08/2025
Oncology
Ran Reshef, MD, MSc
Conference Coverage
Relationship of Cilta-Cel Dose to PFS Outcomes for Patients With R/R Multiple Myeloma: Real-World Analysis
12/08/2025
Higher cell doses of ciltacabtagene autoleucel were associated with improved progression-free survival without added toxicity, according to results from a real-world analysis presented by Ran Reshef, MD, MSc, at the 2025 ASH Annual Meeting &...
Higher cell doses of ciltacabtagene autoleucel were associated with improved progression-free survival without added toxicity, according to results from a real-world analysis presented by Ran Reshef, MD, MSc, at the 2025 ASH Annual Meeting &...
Higher cell doses of...
12/08/2025
Oncology
Adam Cohen, MD
Conference Coverage
Cevostamab Consolidation After BCMA CAR T-Cell Therapy for Patients With R/R Multiple Myeloma: "STEM" Trial
12/08/2025
At the ASH 2025 Annual Meeting, Adam Cohen, MD, shares data from the “STEM” (Sequential T Cell-Engagement for Myeloma) phase 2 trial on cevostamab consolidation following BCMA CAR T-cell therapy for R/R MM.
At the ASH 2025 Annual Meeting, Adam Cohen, MD, shares data from the “STEM” (Sequential T Cell-Engagement for Myeloma) phase 2 trial on cevostamab consolidation following BCMA CAR T-cell therapy for R/R MM.
At the ASH 2025 Annual Meeting,...
12/08/2025
Oncology
Jean-Marie Michot, MD
Conference Coverage
OLYMPIA-3 Trial: Odronextamab With CHOP Demonstrates Strong Efficacy and Manageable Safety for Patients With Newly Diagnosed DLBCL
12/07/2025
Odronextamab combined with CHOP therapy demonstrated high response rates and manageable toxicity among patients with previously untreated diffuse large B-cell lymphoma, according to results presented at the 2025 ASH Annual Meeting.
Odronextamab combined with CHOP therapy demonstrated high response rates and manageable toxicity among patients with previously untreated diffuse large B-cell lymphoma, according to results presented at the 2025 ASH Annual Meeting.
Odronextamab combined with CHOP...
12/07/2025
Oncology
Sairah Ahmed, MD
Conference Coverage
Lisocabtagene Maraleucel Achieves High Responses and Durable 3-Year Remissions for R/R Follicular Lymphoma: TRANSCEND FL
12/07/2025
For patients with at least 3 prior lines of therapy, lisocabtagene maraleucel produced durable, high response rates among patients with R/R follicular lymphoma, according to a 3-year update presented at the 2025 ASH Annual Meeting.
For patients with at least 3 prior lines of therapy, lisocabtagene maraleucel produced durable, high response rates among patients with R/R follicular lymphoma, according to a 3-year update presented at the 2025 ASH Annual Meeting.
For patients with at least 3...
12/07/2025
Oncology
Mitul Gandhi, MD
Conference Coverage
Daratumumab Added to Lenalidomide Maintenance Therapy Following Transplant Improves Depth and Durability of MRD Response for MM: AURIGA Study
12/07/2025
Daratumumab plus lenalidomide maintenance therapy following ASCT improved MRD-negative conversion and durability among newly diagnosed multiple myeloma patients, according to data presented at 2025 ASH Annual Meeting & Exposition.
Daratumumab plus lenalidomide maintenance therapy following ASCT improved MRD-negative conversion and durability among newly diagnosed multiple myeloma patients, according to data presented at 2025 ASH Annual Meeting & Exposition.
Daratumumab plus lenalidomide...
12/07/2025
Oncology

Insights From the ASCO Annual Meeting

Raajit Rampal, MD, PhD
Conference Coverage
Pacritinib Therapy May Improve Hemoglobin Responses Among Patients With Myelofibrosis
09/03/2025
Raajit Rampal, MD, PhD
Raajit Rampal, MD, PhD shares results from a real-world analysis evaluating outcomes and hemoglobin responses among patients with myelofibrosis who were treated with pacritinib.
Raajit Rampal, MD, PhD shares results from a real-world analysis evaluating outcomes and hemoglobin responses among patients with myelofibrosis who were treated with pacritinib.
Raajit Rampal, MD, PhD shares...
09/03/2025
Oncology
John Strickler, MD
Videos
Addition of FOLFIRI to Sotorsaib and Panitumumab Demonstrates Long-Term Efficacy, Safety Among Patients With KRAS G12C-Mutated Metastatic Colorectal Cancer
08/21/2025
John Strickler, MD
John Strickler, MD, discusses results from the CodeBreaK 101 study which assessed the addition of FOLFIRI to sotorasib and panitumumab among patients with KRAS G12C-mutated metastatic colorectal cancer.
John Strickler, MD, discusses results from the CodeBreaK 101 study which assessed the addition of FOLFIRI to sotorasib and panitumumab among patients with KRAS G12C-mutated metastatic colorectal cancer.
John Strickler, MD, discusses...
08/21/2025
Oncology
Amer Zeidan, MBBS, MHS
Conference Coverage
Decitabine-Cedazuridine Plus Venetoclax Therapy Shows Efficacy and Safety for Patients With Newly Diagnosed AML
08/20/2025
Amer Zeidan, MBBS
Amer Zeidan, MBBS, MHS, shares results from a phase 2 trial determining the safety and efficacy of decitabine-cedazuridine plus venetoclax for patients with newly diagnosed acute myeloid leukemia ineligible for induction chemotherapy.
Amer Zeidan, MBBS, MHS, shares results from a phase 2 trial determining the safety and efficacy of decitabine-cedazuridine plus venetoclax for patients with newly diagnosed acute myeloid leukemia ineligible for induction chemotherapy.
Amer Zeidan, MBBS, MHS, shares...
08/20/2025
Oncology
Meghan Mooradian, MD
Conference Coverage
Neoadjuvant Dostarlimab Plus Cobolimab Demonstrates Promise Among Patients With High-Risk Resectable Melanoma
08/12/2025
Meghan Mooradian, MD
Meghan Mooradian, MD, discusses primary analysis results from the phase 2 NEO-MEL-T trial, which showed that neoadjuvant dostarlimab plus cobolimab demonstrated promising efficacy and safety among patients with high-risk resectable melanoma.
Meghan Mooradian, MD, discusses primary analysis results from the phase 2 NEO-MEL-T trial, which showed that neoadjuvant dostarlimab plus cobolimab demonstrated promising efficacy and safety among patients with high-risk resectable melanoma.
Meghan Mooradian, MD, discusses...
08/12/2025
Oncology
Nick James, MD, PhD
Conference Coverage
Use of a Multimodal Artificial Intelligence Algorithm in High-Risk Non-Metastatic Prostate Cancer
08/12/2025
Nicholas James, MD
Nick James, MD, PhD, discusses results from a study which assessed using a multimodal artificial intelligence algorithm to identify patients with high-risk non-metastatic prostate cancer who are most likely to benefit from adding a...
Nick James, MD, PhD, discusses results from a study which assessed using a multimodal artificial intelligence algorithm to identify patients with high-risk non-metastatic prostate cancer who are most likely to benefit from adding a...
Nick James, MD, PhD, discusses...
08/12/2025
Oncology
Stephen Bagley, MD
Conference Coverage
Intracerebroventricular Delivery of CART-EGFR-IL13Rα2 Demonstrates Promise Among Patients With Recurrent Glioblastoma
08/05/2025
Stephen Bagley, MD
Stephen Bagley, MD, discusses results from a phase 1 dose-exploration study which assessed intracerebroventricular delivery of CART-EGFR-IL13Rα2 among patients with recurrent glioblastoma.
Stephen Bagley, MD, discusses results from a phase 1 dose-exploration study which assessed intracerebroventricular delivery of CART-EGFR-IL13Rα2 among patients with recurrent glioblastoma.
Stephen Bagley, MD, discusses...
08/05/2025
Oncology
Zeynep Eroglu, MD
Conference Coverage
First-Line Encorafenib Plus Binimetinib and Nivolumab for Patients With BRAF-Mutated Melanoma Brain Metastases
07/24/2025
Zeynep Eroglu, MD
Zeynep Eroglu, MD, discusses results from the SWOG S2000 study which demonstrated that encorafenib plus binimetinib and nivolumab significantly improved progression-free survival compared to ipilimumab plus nivolumab among patients with...
Zeynep Eroglu, MD, discusses results from the SWOG S2000 study which demonstrated that encorafenib plus binimetinib and nivolumab significantly improved progression-free survival compared to ipilimumab plus nivolumab among patients with...
Zeynep Eroglu, MD, discusses...
07/24/2025
Oncology
Herbert Loong, MD
Conference Coverage
BAY 2927088 Demonstrates Promise Among Patients With HER2-Mutated Non-Small Cell Lung Cancer
07/24/2025
Herbert Loong, MD
Herbert Loong, MD, discusses results from the SOHO-01 trial which showed that BAY 2927088 demonstrated promising efficacy and safety among patients with HER2-mutated non-small cell lung cancer.
Herbert Loong, MD, discusses results from the SOHO-01 trial which showed that BAY 2927088 demonstrated promising efficacy and safety among patients with HER2-mutated non-small cell lung cancer.
Herbert Loong, MD, discusses...
07/24/2025
Oncology
Georgina Long, MD, PhD
Conference Coverage
Addition of Relatimab to Nivolumab Did Not Significantly Improve Outcomes for Patients With Melanoma
07/24/2025
Georgina Long, MBBS, PhD
Georgina Long, MD, PhD, discusses primary results from the RELATIVITY-098 trial, which demonstrated that adjuvant nivolumab plus relatimab did not significantly improve outcomes compared to adjuvant nivolumab monotherapy among patients with...
Georgina Long, MD, PhD, discusses primary results from the RELATIVITY-098 trial, which demonstrated that adjuvant nivolumab plus relatimab did not significantly improve outcomes compared to adjuvant nivolumab monotherapy among patients with...
Georgina Long, MD, PhD,...
07/24/2025
Oncology
Alexander van Akkooi, MD, PhD
Conference Coverage
Adjuvant Encorafenib Plus Binimetinib Demonstrates Promise Among Patients With BRAF-Mutated Melanoma
07/24/2025
Alexander Van Akkooi, MD, PhD
Alexander Van Akkooi, MD, PhD, discusses primary analysis results from the EORTC 2139-MG/Columbus-AD trial which demonstrated that adjuvant encorafenib plus binimetinib demonstrates clinical promise among patients with BRAF-mutated melanoma.
Alexander Van Akkooi, MD, PhD, discusses primary analysis results from the EORTC 2139-MG/Columbus-AD trial which demonstrated that adjuvant encorafenib plus binimetinib demonstrates clinical promise among patients with BRAF-mutated melanoma.
Alexander Van Akkooi, MD, PhD,...
07/24/2025
Oncology

Insights From the ESMO Congress

Stephen Freedland, MD
Videos
Enzalutamide Plus Androgen Deprivation Therapy in Biochemically Recurrent Prostate Cancer
12/02/2025
Stephen J. Freedland, MD
Stephen Freedland, MD, discusses final overall survival results from the EMBARK study, which evaluated enzalutamide plus androgen deprivation therapy in patients with high-risk biochemical recurrence and negative conventional imaging.
Stephen Freedland, MD, discusses final overall survival results from the EMBARK study, which evaluated enzalutamide plus androgen deprivation therapy in patients with high-risk biochemical recurrence and negative conventional imaging.
Stephen Freedland, MD, discusses...
12/02/2025
Oncology
Brian Slomovitz, MD
Videos
Relacorilant Plus Nab-Paclitaxel in Recurrent Platinum-Resistant Ovarian Cancer
12/02/2025
Brian M. Slomovitz, MD, MS
Brian Slomovitz, MD, discusses updated findings from the ROSELLA trial evaluating relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.
Brian Slomovitz, MD, discusses updated findings from the ROSELLA trial evaluating relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.
Brian Slomovitz, MD, discusses...
12/02/2025
Oncology
Pasi Jänne, MD, PhD
Videos
Osimertinib Plus Chemotherapy Provides Broad Survival Benefit in EGFR-Mutant NSCLC
12/02/2025
Pasi Jänne, MD, PhD, discusses subgroup analysis results from the FLAURA2 trial evaluating osimertinib plus platinum-pemetrexed chemotherapy in patients with newly diagnosed EGFR-mutant non-small cell lung cancer.
Pasi Jänne, MD, PhD, discusses subgroup analysis results from the FLAURA2 trial evaluating osimertinib plus platinum-pemetrexed chemotherapy in patients with newly diagnosed EGFR-mutant non-small cell lung cancer.
Pasi Jänne, MD, PhD, discusses...
12/02/2025
Oncology
David Goldstein, MD
Videos
Regorafenib Plus Nivolumab Fails to Improve Outcomes in Gastric or Gastroesophageal Cancer
12/02/2025
David Goldstein, MD, discusses results from the INTEGRATE study which assessed regorafenib plus nivolumab in previously treated patients with gastric or gastroesophageal cancer.
David Goldstein, MD, discusses results from the INTEGRATE study which assessed regorafenib plus nivolumab in previously treated patients with gastric or gastroesophageal cancer.
David Goldstein, MD, discusses...
12/02/2025
Oncology
Sara Lonardi, MD
Videos
Dual Immunotherapy Delivers Durable Benefit in MSI-H/dMMR Metastatic Colorectal Cancer
11/13/2025
Sara Lonardi, MD, shares updated results from CheckMate 8HW comparing nivolumab plus ipilimumab with nivolumab alone or chemotherapy as first-line therapy for patients with MSI-H/dMMR metastatic colorectal cancer.
Sara Lonardi, MD, shares updated results from CheckMate 8HW comparing nivolumab plus ipilimumab with nivolumab alone or chemotherapy as first-line therapy for patients with MSI-H/dMMR metastatic colorectal cancer.
Sara Lonardi, MD, shares updated...
11/13/2025
Oncology
Sanjay Popat, MD, PhD
Videos
First-Line Zongertinib Demonstrates Promise in HER2-Mutated NSCLC
11/13/2025
Sanjay Popat, MD, PhD, discusses results from the phase 2 BEAMION-LUNG 1 trial evaluating zongertinib as a first-line treatment option for patients with advanced HER2-mutated non-small cell lung cancer.
Sanjay Popat, MD, PhD, discusses results from the phase 2 BEAMION-LUNG 1 trial evaluating zongertinib as a first-line treatment option for patients with advanced HER2-mutated non-small cell lung cancer.
Sanjay Popat, MD, PhD, discusses...
11/13/2025
Oncology
Janice Mehnert, MD
Videos
Pembrolizumab Lowers Distant Recurrence Risk in Resected Merkel Cell Carcinoma
11/10/2025
Janice Mehnert, MD
Janice Mehnert, MD, discusses results from the phase 3 STAMP trial evaluating pembrolizumab versus observation in patients with resected merkel cell carcinoma.
Janice Mehnert, MD, discusses results from the phase 3 STAMP trial evaluating pembrolizumab versus observation in patients with resected merkel cell carcinoma.
Janice Mehnert, MD, discusses...
11/10/2025
Oncology
Nima Nabavizadeh, MD
Videos
MCED Blood Test Detects Cancer Early With High Accuracy
11/10/2025
Nima Nabavizadeh, MD
Nima Nabavizadeh, MD, discusses results from the registrational phase 2 PATHFINDER-2 study evaluating an MCED multi-cancer early detection blood test in an intended-use population.
Nima Nabavizadeh, MD, discusses results from the registrational phase 2 PATHFINDER-2 study evaluating an MCED multi-cancer early detection blood test in an intended-use population.
Nima Nabavizadeh, MD, discusses...
11/10/2025
Oncology
Maria De Santis, MD
Videos
Addition of Durvalumab Strengthens Treatment for Patients With High-Risk Non–Muscle Invasive Bladder Cancer
11/10/2025
Maria De Santis, MD
Maria De Santis, MD, discusses results from the phase 3 POTOMAC trial evaluating the addition of durvalumab to bacillus Calmette-Guérin induction and maintenance therapy among patients with high-risk non-muscle invasive bladder cancer.
Maria De Santis, MD, discusses results from the phase 3 POTOMAC trial evaluating the addition of durvalumab to bacillus Calmette-Guérin induction and maintenance therapy among patients with high-risk non-muscle invasive bladder cancer.
Maria De Santis, MD, discusses...
11/10/2025
Oncology
Dean Fennell, MD, PhD
Videos
Intratumor Heterogeneity Predicts Niraparib Benefit in Relapsed Mesothelioma
11/10/2025
Dean Fennell, MD, PhD
Dean Fennell, MD, PhD, discusses results from the investigator-initiated phase 2 NERO trial evaluating niraparib plus active symptom control versus active symptom control alone in patients with relapsed mesothelioma.
Dean Fennell, MD, PhD, discusses results from the investigator-initiated phase 2 NERO trial evaluating niraparib plus active symptom control versus active symptom control alone in patients with relapsed mesothelioma.
Dean Fennell, MD, PhD, discusses...
11/10/2025
Oncology

Live Meetings

Recent News

Conference Coverage
Abemaciclib Plus Endocrine Therapy for HR-Positive, HER2-Negative Advanced Breast Cancer
12/10/2025
Stephanie Holland
Results from the phase 3 AMBRE trial demonstrate that abemaciclib plus endocrine therapy significantly improves PFS compared with investigators choice chemotherapy in patients with HR-positive, HER2-negative advanced breast cancer and high...
Results from the phase 3 AMBRE trial demonstrate that abemaciclib plus endocrine therapy significantly improves PFS compared with investigators choice chemotherapy in patients with HR-positive, HER2-negative advanced breast cancer and high...
Results from the phase 3 AMBRE...
12/10/2025
Oncology
Conference Coverage
Sacituzumab Govitecan Fails to Improve PFS in HR-Positive, HER2-Negative Metastatic Breast Cancer
12/10/2025
Stephanie Holland
According to results from the phase 3 ASCENT-07 trial, sacituzumab govitecan did not significantly improve progression-free survival compared to physician’s choice chemotherapy in previously treated HR-positive, HER2-negative locally advanced...
According to results from the phase 3 ASCENT-07 trial, sacituzumab govitecan did not significantly improve progression-free survival compared to physician’s choice chemotherapy in previously treated HR-positive, HER2-negative locally advanced...
According to results from the...
12/10/2025
Oncology
News
Consolidative Thoracic Radiotherapy Shows Limited Clinical Benefit in Extensive-Stage SCLC
12/10/2025
Stephanie Holland
According to results from the phase 2 SAKK 15-19 trial, consolidative thoracic radiotherapy after chemoimmunotherapy showed limited clinical benefit for patients with extensive-stage small cell lung cancer.
According to results from the phase 2 SAKK 15-19 trial, consolidative thoracic radiotherapy after chemoimmunotherapy showed limited clinical benefit for patients with extensive-stage small cell lung cancer.
According to results from the...
12/10/2025
Oncology
Conference Coverage
Niraparib Plus Dostarlimab Demonstrates Meaningful Neoadjuvant Activity in Germline BRCA1/2-Mutated TNBC
12/10/2025
Stephanie Holland
According to results from the phase 2 TBCRC 056 trial, neoadjuvant niraparib plus dostarlimab demonstrated clinically meaningful pathologic complete response activity among patients with germline BRCA1/2-mutated triple-negative breast cancer.
According to results from the phase 2 TBCRC 056 trial, neoadjuvant niraparib plus dostarlimab demonstrated clinically meaningful pathologic complete response activity among patients with germline BRCA1/2-mutated triple-negative breast cancer.
According to results from the...
12/10/2025
Oncology
Conference Coverage
Belantamab Mafodotin Triplet for R/R MM Shows Sustained Superiority vs Pomalidomide, Bortezomib, and Dexamethasone: DREAMM-8 Long-Term Follow-Up
12/07/2025
Gina Tomaine
Deep responses and durable outcomes were demonstrated among patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the phase 3 DREAMM-8 study presented at the 2025 ASH Annual Meeting.
Deep responses and durable outcomes were demonstrated among patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the phase 3 DREAMM-8 study presented at the 2025 ASH Annual Meeting.
Deep responses and durable...
12/07/2025
Oncology
Conference Coverage
Outcomes of Cilta-Cel Manufacturing for Lenalidomide-Refractory Multiple Myeloma Strongly Influenced by Prior Lines of Therapy
12/06/2025
Emily Estrada
The success of ciltacabtagene autoleucel manufacturing for patients with lenalidomide-refractory MM as early as first relapse decreases with more prior lines of therapy, according to data presented at the 2025 ASH Annual Meeting & Exposition.
The success of ciltacabtagene autoleucel manufacturing for patients with lenalidomide-refractory MM as early as first relapse decreases with more prior lines of therapy, according to data presented at the 2025 ASH Annual Meeting & Exposition.
The success of ciltacabtagene...
12/06/2025
Oncology
Conference Coverage
Talquetamab Plus Teclistamab Demonstrates Durable Efficacy for Patients With R/R MM and Extramedullary Disease: Updated Results from RedirecTT-1 Study
12/06/2025
Emily Estrada
Talquetamab plus teclistamab achieved high response rates for patients with relapsed/refractory multiple myeloma and true extramedullary disease, according to longer follow-up, phase 2 results presented at the 2025 ASH Annual Meeting &...
Talquetamab plus teclistamab achieved high response rates for patients with relapsed/refractory multiple myeloma and true extramedullary disease, according to longer follow-up, phase 2 results presented at the 2025 ASH Annual Meeting &...
Talquetamab plus teclistamab...
12/06/2025
Oncology
Conference Coverage
Identifying Key Predictors of Early Relapse After Treatment With Ciltacabtagene Autoleucel to Inform Risk-Adapted Strategies for Patients With R/R MM
12/06/2025
Emily Estrada
A multicenter analysis presented at the 2025 ASH Annual Meeting identified key predictors of relapse within 18 months of ciltacabtagene autoleucel infusion to improve treatment strategy for patients with high-risk relapsed/refractory multiple...
A multicenter analysis presented at the 2025 ASH Annual Meeting identified key predictors of relapse within 18 months of ciltacabtagene autoleucel infusion to improve treatment strategy for patients with high-risk relapsed/refractory multiple...
A multicenter analysis presented...
12/06/2025
Oncology
Conference Coverage
Cilta-Cel Demonstrates Deep and Durable Responses for Standard-Risk Relapsed/Refractory Myeloma: CARTITUDE-4 Subgroup Analysis
12/06/2025
Emily Estrada
Based on results from the CARTITUDE-4 study presented at the 2025 ASH Annual Meeting, a ciltacabtagene autoleucel infusion achieved durable responses and promising survival outcomes for standard-risk relapsed/refractory multiple myeloma.
Based on results from the CARTITUDE-4 study presented at the 2025 ASH Annual Meeting, a ciltacabtagene autoleucel infusion achieved durable responses and promising survival outcomes for standard-risk relapsed/refractory multiple myeloma.
Based on results from the...
12/06/2025
Oncology
News
Safusidenib Erbumine Shows Promise in Newly Diagnosed IDH1-Mutated Grade 2 Gliomas
12/05/2025
Stephanie Holland
According to results from a phase 2 study, safusidenib erbumine demonstrates promising clinical efficacy and safety among newly diagnosed patients with grade 2 IDH1-mutated gliomas.
According to results from a phase 2 study, safusidenib erbumine demonstrates promising clinical efficacy and safety among newly diagnosed patients with grade 2 IDH1-mutated gliomas.
According to results from a...
12/05/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use